Your browser is no longer supported. Please, upgrade your browser.
SUPN Supernus Pharmaceuticals, Inc. daily Stock Chart
Supernus Pharmaceuticals, Inc.
Index- P/E11.17 EPS (ttm)2.16 Insider Own1.60% Shs Outstand52.54M Perf Week4.64%
Market Cap1.27B Forward P/E13.31 EPS next Y1.82 Insider Trans-3.53% Shs Float50.64M Perf Month-0.54%
Income116.20M PEG0.30 EPS next Q0.35 Inst Own96.90% Short Float8.99% Perf Quarter3.21%
Sales402.30M P/S3.17 EPS this Y2.40% Inst Trans-0.25% Short Ratio9.40 Perf Half Y0.63%
Book/sh11.68 P/B2.07 EPS next Y21.98% ROA10.30% Target Price29.00 Perf Year-10.59%
Cash/sh7.60 P/C3.18 EPS next 5Y37.00% ROE20.30% 52W Range13.12 - 29.81 Perf YTD1.81%
Dividend- P/FCF11.18 EPS past 5Y58.90% ROI12.10% 52W High-18.99% Beta1.52
Dividend %- Quick Ratio3.20 Sales past 5Y33.50% Gross Margin95.70% 52W Low84.07% ATR0.92
Employees464 Current Ratio3.30 Sales Q/Q11.10% Oper. Margin37.80% RSI (14)57.03 Volatility4.41% 3.58%
OptionableYes Debt/Eq0.57 EPS Q/Q18.20% Profit Margin28.90% Rel Volume1.04 Prev Close23.35
ShortableYes LT Debt/Eq0.57 EarningsMay 05 AMC Payout0.00% Avg Volume484.33K Price24.15
Recom2.50 SMA203.40% SMA502.32% SMA2008.53% Volume502,695 Change3.43%
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Oct-28-15Initiated Northland Capital Outperform $26
Aug-12-20 07:29AM  
Aug-11-20 04:30PM  
Aug-10-20 08:36AM  
Jul-30-20 12:10PM  
Jul-28-20 12:33PM  
Jun-26-20 06:29PM  
Jun-19-20 01:47AM  
Jun-11-20 12:27PM  
Jun-09-20 03:46PM  
Jun-02-20 10:00AM  
May-27-20 04:30PM  
May-15-20 04:15PM  
May-09-20 04:17PM  
May-07-20 05:30PM  
May-05-20 08:25PM  
Apr-30-20 09:40AM  
Apr-29-20 08:40AM  
Apr-28-20 05:00PM  
Apr-24-20 04:30PM  
Apr-21-20 04:15PM  
Apr-15-20 11:21AM  
Mar-30-20 05:20PM  
Mar-16-20 10:34AM  
Mar-13-20 11:16AM  
Mar-09-20 01:30PM  
Feb-26-20 01:14PM  
Feb-25-20 05:55PM  
Feb-17-20 01:22PM  
Feb-11-20 04:05PM  
Jan-22-20 08:25AM  
Jan-21-20 06:33PM  
Jan-16-20 10:59AM  
Jan-08-20 10:30AM  
Dec-16-19 02:00PM  
Dec-11-19 08:52AM  
Dec-10-19 07:56AM  
Dec-09-19 04:15PM  
Nov-19-19 02:18PM  
Nov-12-19 06:14PM  
Nov-11-19 04:15PM  
Nov-09-19 03:46AM  
Nov-08-19 03:53AM  
Nov-07-19 07:18AM  
Nov-06-19 08:21AM  
Nov-05-19 06:45PM  
Oct-29-19 10:32AM  
Oct-28-19 08:53AM  
Oct-24-19 04:10PM  
Oct-22-19 03:49PM  
Oct-02-19 01:04PM  
Sep-25-19 02:21PM  
Sep-13-19 01:54PM  
Sep-02-19 09:50AM  
Aug-30-19 06:00AM  
Aug-27-19 07:15PM  
Aug-26-19 11:20AM  
Aug-15-19 05:07PM  
Aug-14-19 10:13AM  
Aug-07-19 11:23PM  
Aug-06-19 08:15PM  
Jul-24-19 07:11AM  
Jul-23-19 04:34PM  
Jul-11-19 12:58PM  
Jun-17-19 12:39PM  
Jun-11-19 11:04AM  
Jun-05-19 07:04AM  
May-30-19 03:03PM  
May-29-19 04:15PM  
May-16-19 08:10AM  
May-08-19 03:00PM  
May-07-19 10:14PM  
May-05-19 10:22AM  
May-01-19 11:55AM  
Apr-30-19 10:32AM  
Apr-29-19 09:17AM  
Apr-24-19 04:15PM  
Apr-18-19 08:08AM  
Apr-01-19 04:46PM  
Mar-28-19 08:29PM  
Mar-27-19 06:03PM  
Mar-14-19 10:41AM  
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hudson Frederick M.DirectorJul 13Option Exercise2.568,75022,40018,961Jul 15 04:39 PM
Hudson Frederick M.DirectorJul 13Sale24.4492022,48518,041Jul 15 04:39 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Option Exercise12.9815,000194,70061,057May 20 06:59 PM
PATRICK GREGORY SSr.VP, Chief Financial OfficerMay 20Sale25.0315,000375,38046,057May 20 06:59 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Option Exercise9.1315,000136,95061,057May 11 06:42 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerMay 08Sale23.1415,000347,03446,057May 11 06:42 PM
Khattar Jack A.President, CEOAug 23Buy26.397,200189,982465,141Aug 27 05:27 PM